

1 **Title: Neuroimmune transcriptome changes in brains of psychiatric and**
2 **neurological disorder patients**

3 **Authors:** Yu Chen^{1,2}, Jiacheng Dai^{1,3}, Longfei Tang¹, Tatiana Mikhailova⁵, Qiuman Liang¹,
4 Miao Li¹, Jiaqi Zhou¹, Cynthia Weickert⁵, Chao Chen^{1,4*}, Chunyu Liu^{1,5*}

5 **Affiliations:**

6 ¹ Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life
7 Sciences, and Department of Psychiatry, The Second Xiangya Hospital, Central South
8 University, Changsha, 410078, China

9 ² Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA

10 ³ State Key Laboratory of Genetic Engineering, Human Phenome Institute, and School of
11 Life Sciences, Fudan University, Shanghai, 200438, China

12 ⁴ Hunan Key Laboratory of Animal Models for Human Diseases, Central South University,
13 Changsha, 410078, China

14 ⁵ Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA

15 *Corresponding authors. Email: chenchao@sklmg.edu.cn; LiuCh@upstate.edu

16 Running Title: Immune changes in disordered brains

17 Key words: neuroimmune, neurological diseases, psychiatric disorders, cross-disorder
18 analysis, transcriptome, gene expression

19 Word length of each section Abstract: 182; Introduction: 498; Results: 2174; Discussion:

20 1697

21 **Abstract:**

22 Neuroinflammation has been implicated in multiple brain disorders but the extent and the
23 magnitude of change in immune-related genes (IRGs) across distinct brain disorders has not been
24 directly compared. We curated 1,275 IRGs and investigated their expression changes in 2,467
25 postmortem brains of controls and patients with six major brain disorders, including
26 schizophrenia (SCZ), bipolar disorder (BD), autism spectrum disorder (ASD), major depressive
27 disorder (MDD), Alzheimer's disease (AD), and Parkinson's disease (PD). More than 60% of the
28 IRGs had significantly altered expression in at least one of the six disorders. The differentially
29 expressed immune-related genes (dIRGs) shared across disorders were mainly related to innate
30 immunity. Moreover, we systematically evaluated sex, tissue, and cell type for immune
31 alterations in different neuropsychiatric disorders. Co-expression networks revealed that
32 neuroimmune systems interacted with neuronal-systems, both of which contribute to the risk of
33 disorders. However, only a few genes with expression changes have also been identified as
34 containing risk variants of genome-wide association studies. The transcriptome alterations at
35 gene and network levels may clarify the immune-related pathophysiology and redefine
36 neuropsychiatric and neurological disorders.

37 **One-Sentence Summary:** The brain transcriptome of six neurological and psychiatric disorders
38 showed signature changes in genes related to immunity.

39

40

41 **Introduction**

42 Multiple lines of evidence support the notion that the immune system is involved in major “brain
43 disorders,” including psychiatric disorders such as schizophrenia (SCZ) (1), bipolar disorder
44 (BD) (2), and major depressive disorder (MDD)(3), brain development disorders such as autism
45 spectrum disorder (ASD)(4), and neurodegenerative diseases such as Alzheimer's disease
46 (AD)(5), and Parkinson's disease (PD)(6). Patients with these brain diseases share deficits in
47 cognition, blunted mood, restricted sociability and abnormal behavior to various degrees.

48 Transcriptome studies have identified expression alterations of immune-related genes (IRGs) in
49 postmortem brains of AD(7) , PD(8) , ASD(9) , SCZ(10-14) and BD(10) separately. Cross-
50 disorder transcriptomic studies further highlighted changes in IRGs(15, 16). At the protein level,
51 several peripheral cytokines showed reproducible disease-specific changes in a meta-analysis
52 (17). Since brain dysfunction is considered the major cause of these disorders, studying immune
53 gene expression changes in patient brains may reveal mechanistic connections between immune
54 system genes and brain dysfunction. Most previous studies were limited to the analysis of
55 individual disorders. There is no comprehensive comparison of the pattern and extent of
56 inflammation-related changes in terms of immune constructs (subnetworks), neuro-immune
57 interaction, genetic contribution, and relationship between diseases.

58 Neuroinflammation, an immune response taking place within the central nervous system (CNS),
59 can be activated by psychological stress, aging, infection, trauma, ischemia, and toxins (18, 19).
60 It is regulated by sex (20), tissue type (21) and genetics (22), many of which are known disease
61 risk factors for both psychiatric and neurological diseases. The primary function of
62 neuroinflammation is to maintain brain homeostasis through protection (23) and repair (24).

63 Abnormal neuroinflammation activation could lead to dysregulation of mood (25), social
64 behaviors (26), and cognitive abilities (27). Offspring who were fetuses when their mothers'
65 immune system was activated (MIA) showed dopaminergic hyperfunction (28), cognitive
66 impairment (29), and behavioral abnormalities (30) as adults. Alternatively, acute and chronic
67 neuroinflammation in adulthood can also alter cognition and behavior(31, 32). In animal models,
68 both adult and developmental maternal immune activation in the periphery can lead to increases
69 in pro-inflammatory cytokines in the brain , similar to what is found in humans with major
70 mental illness(14, 33).

71 Previous studies identified immune gene dysregulations in brains of patients with several major
72 brain disorders. For example, Gandal et al.(16) found that up-regulated genes and isoforms in
73 SCZ, BD, and ASD were enriched in pathways such as inflammatory response and response to
74 cytokines. One brain co-expression module up-regulated specifically in MDD was enriched for
75 genes of cytokine-cytokine interactions, and hormone activity pathways(15). The association of
76 neurological diseases such as AD and PD with IRGs has also been reported(7, 34). These studies
77 examined the changes of immune system as a whole without going into details of specific
78 subnetworks, the disease signature, or genetic versus environmental contribution.

79 We hypothesize that expression changes of specific subsets of IRGs constitute part of the
80 transcriptome signatures that distinguishes diseases. Since tissue specificity, sex and genetics all
81 could influence such transcriptome signatures, we analyzed their effects. Furthermore, we expect
82 that neurological diseases and psychiatric disorders bear transcriptomic changes that may help to
83 address how similar immunological mechanisms lead to distinct brain disorders. The current
84 boundary between neurological diseases and psychiatric disorders is primarily the presence of
85 known pathology. Neurological diseases have more robust histological changes while psychiatric

86 disorders have more subtle subcellular changes. Nonetheless, pathology evidence is always a
87 subject to be revised with new research.

88 To investigate immune-related signatures of transcriptome dysregulation in brains of six
89 neurological and psychiatric disorders, we studied a selected list of 1,275 genes known to be
90 associated with neuroinflammation and interrogated their expression across disorders. We
91 collected and analyzed existing transcriptome data of 2,467 postmortem brain samples from
92 donors with AD(35-37), ASD(38-41), BD(38, 42-45), MDD(44, 46), PD(47-50), SCZ(38, 42-45,
93 51, 52) and healthy controls (CTL). We identified the differentially expressed IRGs shared
94 across disorders or specific to each disorder, and their related coexpression modules (Fig. S1).
95 These genes and their networks and pathways provided important insight into how immunity
96 may contribute to the risk of these neurological and psychiatric disorders, with a potential to
97 refine disease classification.

98

99

100 **Results**

101 **Expressions of immune-related genes were altered in brain disorders.**

102 We collected 1,789 IRGs from curated databases including Comparative Toxicogenomics
103 Database(53), ImmPort(54), ImmunomeDB(55), InnateDB(56), ImmuneSigDB(57), Gene
104 Ontology database with immune annotation(58), KEGG database with immune annotation(59),
105 as well as additional literature reviews (60-62), followed by filtering based on expression profile
106 in the human brains (see Table. S1). We compiled 23 transcriptomic datasets of multiple brain
107 disorders from the Gene Expression Omnibus (GEO), ArrayExpress, or from the authors directly
108 (see Table. S1). In total, we collected transcriptome data of 2,467 postmortem brain samples
109 from subjects with AD (n = 340 individuals), ASD (n = 103), BD (n = 188), MDD (n =87), PD
110 (n = 97), SCZ (n = 474) and CTL (n = 1,178). We used the data sets derived from microarray
111 (n=1007) as our discovery set and data sets derived from RNA-Seq as an independent replication
112 set (Table. S1). Out of the 1,789 selected IRGs, 1,275 (71%) were detected across all the
113 microarray data. The IRG curation procedure is summarized in a Preferred Reporting Items for
114 Systematic Reviews and Meta-Analyses (PRISMA) workflow (Fig. S2). **Table S2** lists the 1,275
115 detected IRGs categorized by their reference databases and pathway annotation programs.

116 After preprocessing the microarray data (methods and materials), we conducted a whole
117 transcriptome differential expression analysis for each disorder using a linear mixed-effects
118 model that accounted for sample overlap across studies. Filtering the differentially expressed
119 genes (DEGs, FDR<0.05) for the 1,275 IRGs, we identified dIRGs in each of the six brain
120 disorders (number of dIRGs in descending order of transcript identified as differentially

121 expressed; AD: 638, ASD: 275, SCZ: 220, PD: 97, BD: 58, MDD: 27, Fig. 1A). We used a
122 conservative genome-wide threshold instead of study-wide threshold for significance so that we
123 could further evaluate the relative enrichment of IRGs in all the DEGs under the same
124 significance criteria. The dIRGs were significantly over-represented in the DEGs across
125 disorders ($OR > 2$, $adjust.p < 0.05$, Table S3). The enrichment of IRGs in the DEGs supports the
126 reported immune gene dysfunction in transcriptome of these six disorders, highlighting its
127 importance.

128 To replicate the findings, we used the independent RNA-seq datasets and processed data as
129 detailed in the Methods and Materials. We observed a significant overlap of dIRGs between
130 discovery and replicate datasets (Table S4). AD data achieved the highest replication rate (56%)
131 while BD achieved the lowest (19%). More importantly, we observed high concordance of effect
132 sizes of case-control fold change between the microarray and RNA-seq results for all IRGs ($R^2 >$
133 0.66 , $p.value < 2.2E-16$, Fig. 1B, Table S4).

134 **The changes of IRGs clustered by disorders and sex- and tissue-specific effects.**

135 We used hierarchical clustering based on the correlations of the fold changes of all the detected
136 IRGs among different brain disorders, resulting in two distinct groups, one containing all
137 psychiatric disorders (BD, SCZ, and MDD) and another containing mainly neurological
138 disorders (ASD, AD, and PD) (Fig. 2A, B). The fold changes of IRGs were highly correlated
139 between SCZ and BD (Spearman's $r = 0.75$, $p.value < 0.001$). When comparing the groups of
140 psychiatric disorders and neurological disorders, we found a higher effect size (larger fold-
141 change) in the expression of inflammatory related genes in neurological disorders than in
142 psychiatric disorders ($t-test p.value < 2.2E-16$, Fig. S4). RNA-seq data replicated the observation

143 (Fig. S4) that larger immune-related dysregulation was present in neurological disorders than in
144 psychiatric disorders.

145 To test effects of sex on immune-related dysregulation, we recomputed dIRGs with the samples
146 partitioned by sex. Comparing the effect sizes of the IRGs between male and female subgroups,
147 we found significant sex differences in ASD and MDD (Fig. 2C, Table. S5; $p_{ASD} = 0.003$; p_{MDD}
148 $= 4E-6$), but not in other diseases. The IRGs showed larger magnitude of change in male ASD
149 than in female ASD relative to corresponding controls, while the situation was the opposite for
150 MDD with females having larger changes than males.

151 To investigate tissue specificity of IRG dysregulation, or more specifically, whether alterations
152 of IRGs in the brain can be reflected in blood, we calculated the changes of IRGs in blood
153 datasets of these six disorders (Table S1). The correlation of IRGs' effect size showed negligible
154 concordance (R^2 from -0.24 to 0.11, P -value > 0.05 , Fig. S5), indicating that the majority of the
155 changes of IRGs in the blood and brain do not overlap, implying distinct origins and/or cellular
156 mechanisms. However, we still identified a few dIRGs showing consistent changes in brain and
157 blood (Table S6), such as S100A8 in SCZ. These genes may serve as candidates of disease
158 peripheral biomarkers, which warrants a thorough investigation.

159 **Innate immune genes are the most shared changes across all brain disorders.**

160 Comparing the overlap of dIRGs across disorders, 26% of IRGs were dIRGs in two or more
161 disorders (shared dIRGs, Fig. 3 A, B). While we found alterations of both adaptive and innate
162 IRGs in each disease (Fig. S6, Table S3), 68% of the shared dIRGs were classified as genes
163 involving innate immune functions. To avoid bias caused by the number of IRGs in the two
164 categories, we further calculated the enrichment of dIRG and found that they were significantly

165 enriched in only innate IRGs (Fisher Exact Test OR > 2, qvalue <0.05). In the RNA-seq replicate
166 data, there was a better replication rates in innate IRGs than in adaptive IRGs (Fig. S6, Table S4).

167 The two most shared dIRGs are Corticotropin-releasing hormone (CRH) and Tachykinin
168 Precursor 1 (TAC1), which were differentially expressed in five of the six diseases (Fig. 2D).
169 They both involve innate immunity according to the databases we used and literature (53-56, 58,
170 59). CRH was downregulated in five of the six disorders; the exception was PD. CRH can
171 regulate innate immune activation with neurotensin (NT), stimulating mast cells, endothelia, and
172 microglia (57). TAC1 was down-regulated in five of the six disorders, the exception being MDD.
173 TAC1 encodes four products of substance P, which can alter the immune functions of activated
174 microglia and astrocytes (63). Independent RNA-seq data confirmed both CRH and TAC1
175 findings. These transcripts are also neuromodulators and have action on neurons so they have
176 roles in addition to immune functions.

177 To identify specific immune pathways that dIRGs are involved in, we further tested the
178 enrichment of the dIRGs in specific immune functions. We found six dIRGs-enriched pathways
179 shared by all six disorders. "Regulation of innate immune response (GO:0045088)" was one of
180 the six pathways (q.value< 0.05, Table. S7, Fig. 3E). When a subset of the innate immune genes
181 as defined by the GO database was used as input instead of all IRGs, hierarchical clustering
182 resulted in the same clusters of psychiatric vs. neurological diseases (Fig. S7). This indicated that
183 even though immune dysfunction is widespread in the six disorders, signature patterns of the
184 subset innate immune genes are sufficient to differentiate neurological from psychiatric
185 disorders.

186 **Immune-related coexpression modules (IRMs) shared by diseases were related to brain**
187 **development and aging.**

188 To determine if neuroimmunity works in silos or cooperates with other functions, we used robust
189 weighted gene coexpression network analysis (rWGCNA)(64) to construct immune-related co-
190 expression networks on the whole transcriptome. We identified 16 brain co-expression networks
191 shared across disorders (Fig. 4A, Fig. S7) after adjusting the batch covariate. Three of the 16
192 networks were enriched for IRGs and were called immune-related co-expression modules (Fig.
193 4B, C; IRM4, IRG enrichment q.value = 2.15E-2; IRM12, q.value = 1.13E-04; IRM14, q.value =
194 9.29E-12). These three IRMs were significantly associated with at least two disorders in the
195 same direction (Fig. 4D). The Eigengene (hub gene) of IRM4 was negatively associated with all
196 disorders (Fig. 4D). IRM4 was enriched for neuron markers (Fig. 4E). Two of the modules
197 (IRM12 and IRM14) were enriched with microglia and endothelial marker genes (Fig. 4E),
198 respectively, and were both positively associated with IRGs in AD and ASD (Fig. 4D). AD had
199 the strongest association with all three IRMs (Fig. 4D). The endothelial-related IRM14 and
200 neuron-related IRM4 were both enriched for tissue development (q.value= 6.69E-5, Fig. 4F,
201 Table S8) and neuron development (q.value= 6.49E-11, Fig. 4F, Table S8). Additionally, the
202 IRM4 was significantly enriched for late fetal cortical markers (q.value= 1.921E-07, Table. S8).

203 We also assessed the influence of age on the IRMs and found that the age trajectories of these
204 IRMs in cases had distinct patterns across disorders (Fig. S7D), which further illustrated the
205 disease-specific temporal dynamics of these IRMs. For example, the neuron-related IRM-4 genes
206 are continuously up-regulated in AD, with inverted U-shaped curve peaking at age ~ 80, while
207 PD shows a continuous downward trend in the same age range.

208 **Disease-specific IRMs in AD, ASD, and PD imply distinct biological processes.**

209 We also searched for disease-specific IRMs for each disorder. We used rWGCNA to construct
210 brain co-expression networks in the brains of each disorder and of controls, then compared them
211 against each other to identify **disease-specific IRMs** (Fig.5A). Based on preservation results of
212 one disease versus controls and against all other diseases (Fig. 5B, z-summary < 10), as well as
213 immune gene enrichment results (Table S9; enrichment q.value < 0.05), we identified six
214 disease-specific IRMs, including one for AD, three for ASD, and two for PD. We did not detect
215 disease-specific IRMs for SCZ, BD, or MDD, which are considered psychiatric disorders.

216 The disease-specific IRMs were enriched for various functions (Fig. 5C, Table S9). The AD-
217 specific IRM was enriched for neuron part (GO:0097458, q.value= 4.57E-4) and presynapse
218 (GO:0098793, q.value = 4.57E-4). The PD-specific IRM was enriched for positive regulation of
219 angiogenesis (GO:0045766, q.value = 9.65E-06) and secretory granule (GO:0030141, q.value=
220 6.31E-06). The ASD-specific IRMs were enriched for developmental biological processes such
221 as negative regulation of cell proliferation (GO:0008285, q.value= 1.21E-4) and growth factor
222 receptor binding (GO:0070851, q.value = 1.27E-02).

223 **Common SNPs have a modest contribution to neuroimmune changes.**

224 We used two different approaches to further explore whether the altered IRGs in brain disorders
225 were influenced by common SNPs. We examined sharing between dIRGs and disease GWAS
226 signal genes and the correlation relationships between pairs of disorders for their changes of
227 dIRGs and disease heritability calculated by GWAS.

228 We tested whether dIRGs, dIRG-enriched pathways, and IRMs were enriched for disease GWAS
229 signals. We found a few dIRGs overlapping with genes that are located in GWAS loci for all six
230 diseases, with AD having the largest number of genes (35 genes), and SCZ the second-largest

231 (15 genes), including IL6R in AD, C4A in the SCZ. (Table S10). A few dIRG-related pathways
232 were significantly enriched in AD and SCZ GWAS signals and survived multiple testing
233 corrections (Table S10). Among them, the amyloid precursor protein catabolic process was
234 enriched in AD GWAS signals (q.value= 3.9E-7). The leukocyte apoptotic process was enriched
235 in SCZ GWAS signals (q.value= 0.03). Only IRM-4 was enriched in SCZ GWAS signals (Table
236 S10).

237 When two disorders have similar genetic risks, will they have similar changes of IRGs? In other
238 words, is the genetic similarity between two disorders reflected by the similarity of expression
239 changes of IRGs? We assessed the relationship between the effect-size correlation of dIRGs and
240 the genetic correlation from the same pairs of disorders(15). The genetic correlation was
241 obtained from the Brainstorm Consortium(65). Putting all the pairs of disorders together, we
242 obtained a correlation of these two kinds of correlations, modest correlation by r value, but
243 insignificant by p value (Fig. S8, Pearson' r = 0.46, p.value = 0.08). Though there was a small
244 sample size of pairs of disorders (N=15) in this analysis, the analysis suggested that genetic
245 factors had a minor contribution to general brain disorders through affecting the IRGs. This
246 analysis captures collective contributions from all six disorders and cannot resolve individual
247 contributions.

248

249 **Discussion**

250 Our study focused on the neuroimmune changes represented by gene expression in multiple
251 neuropsychiatric and neurological disorders. We used transcriptome data of more than 2,000
252 brains from healthy controls and patients of six major brain disorders. By studying individual
253 IRGs and related pathways and coexpression networks, we found that brain disorders have both
254 shared and disease-specific immune-related changes. In addition, we evaluated the effects of
255 biological factors such as tissue, sex, age, and cell type. We came up with four major findings of
256 the neuroimmune system in brains of different neuropsychiatric disorders: 1) the innate immune
257 system carries more alterations than the adaptive immune systems in the six disorders; 2) the
258 altered immune systems interact with other biological pathways and networks contributing to the
259 risk of disorders; 3) common SNPs have a limited contribution to immune-related disease risks,
260 suggesting the environmental contribution may be substantial; and 4) the expression profiles of
261 dIRGs, particularly that of innate immune genes, group neurodevelopment disorder ASD with
262 neurological diseases (AD and PD) instead of with psychiatric disorders (BD, MDD, and SCZ)

263 Dysregulation of the innate immune system is a common denominator for all six brain disorders.
264 We found that more than half of the shared dIRGs and dIRG-enriched pathways were related to
265 the innate immune system. The two most shared dIRGs, TAC1 and CRH, have known effects on
266 innate immune activation(66, 67). Both genes were downregulated in patient brains.

267 Additionally, TLR1/2 mediates microglial activity, which could contribute to neuronal death
268 through the release of inflammatory mediators(68). Furthermore, innate immunity is critical in
269 maintaining homeostasis in the brain. For example, the innate immune system has been reported
270 to function in the CNS's resilience(69) and in synaptic pruning throughout brain growth(70).

271 When homeostasis is disrupted, the abnormal innate immunity may impact a wide range of brain
272 functions(71).

273 Concerning tissue specificity, our results indicated that there are huge differences in immune
274 transcriptomes between blood and brain in patients with brain disorders, highlighting the
275 importance of studying immune systems in brain. This inconsistency can be caused by the blood-
276 brain barrier, which separates the CNS from the peripheral circulation. CNS and blood have
277 independent responses to immune-related insults(72).

278 Microglia are highlighted in the immune changes in brains of AD and ASD in this study.
279 Microglia is the major cell type participating in the brain's immune system. Our analyses showed
280 that the IRM12 coexpression module was enriched for microglia genes and associated with
281 inflammatory transcriptional change in AD and ASD but not the other four diseases. Does this
282 suggest that microglial dysfunction contributes more to AD and ASD than to the other disorders?
283 The PsychENCODE study showed the microglial module upregulated in ASD and
284 downregulated in SCZ and BD(16), but the fold changes in SCZ and BD were much smaller than
285 that in ASD (Fig 7.B in original paper(16)). Larger sample size may be needed to detect
286 microglia contribution to other disorders such as SCZ and BD.

287 Sex contributes to the disease-related immune changes too. Our results revealed sex-bias
288 dysregulation of IRGs in brains of ASD and MDD but not in other disorders. These two
289 disorders are known to have sex differences in prevalence(73-75). Previous studies also have
290 suggested that sex differences in stress-related neuroinflammation might account for the overall
291 sex bias in stress-linked psychiatric disorders, including female bias in MDD(76) and male bias
292 in ASD(77). We did not observe sex-biased IRGs in other diseases with known sex-biased

293 prevalence, such as SCZ and AD suggesting that sex differences in SCZ and AD may not
294 involve IRG changes.

295 The dIRGs are expected to be enriched for immune-related pathways since we selected genes
296 from immune systems. Therefore, it is more interesting to learn how the neuroimmune system
297 cooperates with other brain-related biological processes to influence the disease risk. Our
298 coexpression network analyses suggested that IRGs' changes in patients' brains were involved in
299 developmental processes. Three brain universal IRMs were also enriched with functions related
300 to development in neurons, microglia, and endothelia. Among them, IRM4 is of particular
301 interest for connecting neuron, immune system, and development to all six disorders tested in
302 this study. The contribution of neuro-immune-development to SCZ and ASD is well accepted.
303 Previous studies discovered the role of the immune system in the development of the CNS(69, 78,
304 79). Abnormal immune activation during brain development can cause behavioral and
305 neurochemical abnormalities relevant to disorders(80-84). One additional disease-specific
306 module, ASD-IRM6, is also associated with development, further implicating the importance of
307 development in ASD risk. The connections between AD, PD, and neuro-immune-development
308 through IRM4 remain unclear, as they are late-onset neurodegenerative diseases. The unique age
309 trajectories of these IRM4 in AD patients suggested aging in the immune system was involved
310 for the same set of genes.

311 Our results showed how immune system dysregulation may influence gene expression of the
312 networked other non-immune genes and contribute to the pathology of these diseases specifically.
313 Six disease-specific IRMs were detected in AD, ASD, and PD, showing that several functions of
314 the immune-related networks also involved in corresponding disorders such as presynaptic-
315 related AD-IRM and Growth factor receptors-related ASD-IRMs. Presynaptic proteins are

316 essential for synaptic function and are related to cognitive impairments in AD(85). Growth factor
317 receptors(86) and N-acetylcysteine(87) are involved in the etiology of ASD. Secretogranin may
318 be a pivotal component of the neuroendocrine pathway and play an essential role in neuronal
319 communication and neurotransmitter release in PD (88). Furthermore, the immune system has
320 been found to regulate presynaptic proteins(89), EGFR(90), and secretogranin(88). Our results
321 indicate that alterations of the immune network can be disease-specific, affecting specific
322 coexpression networks and driving distinct risk of each disorder.

323 Debate exists over whether neuroinflammatory alterations in disorders are affected by common
324 SNPs(91, 92) or by the environment(93, 94). This study offered support for both arguments. On
325 the genetic risk side, we did not detect statistically significant correlation between overall genetic
326 risk and IRG changes between pairs of disorders. This IRG-subset result is in contrast with the
327 results on whole transcriptome(15) where a significant correlation with Spearman's $\rho = 0.79$ was
328 reported. Such difference suggests the environmental contributions to the immune-related risks
329 in these disorders. dIRGs were not significantly enriched in any disease GWAS signals. A
330 number of dIRGs are also GWAS signals such as IL6R in AD and C4A in SCZ. IL6R has been
331 identified as a strong candidate gene of AD with both genetic and transcriptome supports(95).
332 C4A is a well-known risk gene which was identified by SCZ GWAS and is up-regulated in SCZ
333 (effect size=0.2, qvalue<0.05). Several dIRG-related pathways and coexpression modules were
334 enriched in GWAS signals of neurological diseases AD and SCZ, respectively. Enrichment for
335 AD was particularly strong, involving the amyloid precursor protein catabolic process in AD. A
336 previous study identified this pathway, which is under genetic control in AD(96). The genetic
337 connection with immunity detected here is certainly indirect. We did not detect any significant
338 enrichment of dIRG in GWASs of ASD, PD, BD, and MDD. The genetic contribution to
339 neuroinflammation may be more relevant to AD and SCZ than the other four disorders. Our

340 interpretation is that the immune contributions to the risks of all these disorders were mostly
341 related to the environment.

342 The environmental contribution to neuropsychiatric disease risk is strongly implicated through
343 immunity. Our data suggests that these brain diseases are related to stress, an environmental
344 factor. CRH is one of the most shared dIRGs across disorders. CRH has the core function of
345 controlling the release of stress hormones. Studies have reported the relationship between
346 immunity and stress(97, 98) and showed patients with brain disorders had decreased cortisol
347 responses to social stressors(77). BD-specific immune-related pathway is reflected in genes
348 changed in a mouse stress model, further emphasizing the contribution of stress to BD.

349 To our surprise, neurodevelopment disorder ASD was grouped with neurological diseases (AD
350 and PD) instead of with psychiatric disorders (BD, MDD, and SCZ) according to the changes of
351 IRGs, particularly innate immune genes. Hierarchical clustering analysis based on the effect size
352 of IRGs placed the presumed psychiatric disorder ASD with other neurological diseases.

353 Previous studies have reported that ASD patients exhibited more neurological and
354 immunological problems(99-102) compared to healthy people and to other brain disorders. As
355 more etiologies are uncovered, the traditional classification of these diseases is increasingly
356 challenged(93). Furthermore, we found that dIRGs change more in neurological diseases (AD,
357 PD, and ASD) than in the psychiatric disorders (BD, SCZ, and MDD). It suggested that
358 neuroimmunity dysregulation is more severe in neurological diseases than in psychiatric
359 disorders, led by AD. Neuroimmunity may help to redefine disease classification in the future.

360 Our study has several limitations. It should be noted that the disease-specific results in our study
361 could be influenced by statistical power and sample heterogeneity. More data will be needed to
362 develop the disease-specific signatures of neuropsychiatric disorders in the future. The difference

363 in numbers of dIRG among disorders might be related to the sample size of each disease dataset.
364 However, the sample size cannot explain all the differences. BD (n=188) has more samples than
365 ASD (n=103) and PD (n=97), but has fewer dIRGs, suggesting BD involves fewer immune
366 changes in the brain than most other disorders. In contrast, AD has possibly the most inflamed
367 brain with more dIRGs than all other disorders, but its sample size is smaller than SCZ. We used
368 transcriptome data from bulk tissues, which did not reflect the expression of immune genes in
369 specific brain cell types. In our statistical procedure, we have used SVA to control hidden
370 covariates, which minimized the cell type effects. The coexpression network analysis still
371 suggested three cell types. Single-cell or deconvolutional data will be needed to study subtypes
372 of cells specifically. Age and other factors may influence immune response. We have regressed
373 out those factors when detecting dIRGs too. In order to resolve causal relationship between
374 neuroinflammatory changes and disorders, longitudinal study will be needed.

375 In summary, our results provided a cross-disorder transcriptome study to explore the
376 neuroimmune system dysfunction in six neurological and psychiatric disorders. More than 60%
377 of the IRGs had significantly altered expression in at least one of the six disorders. The
378 functional annotations of the dIRGs highlighted the shared dysfunction of innate immunity, and
379 its ability to differentiate psychiatric disorders from neurological diseases. Disease-specific
380 dIRGs and their associated pathways and coexpression modules may explain the distinct clinical
381 features of each disorder. Stress environment may have a dominant effect on the observed
382 changes. Our study suggests that therapeutic targeting of different components of the systems
383 may lead to distinct effects: some are general for all brain disorders while others could help
384 specific disorders.

385

References and Notes

- 386 1. D. Parshukova *et al.*, Autoimmunity and immune system dysregulation in schizophrenia:
387 IgGs from sera of patients hydrolyze myelin basic protein. *J Mol Recognit* **32**, e2759
388 (2019).
- 389 2. F. Benedetti, V. Aggio, M. L. Pratesi, G. Greco, R. Furlan, Neuroinflammation in Bipolar
390 Depression. *Front Psychiatry* **11**, 71 (2020).
- 391 3. R. Resende *et al.*, Mitochondria, endoplasmic reticulum and innate immune dysfunction
392 in mood disorders: Do Mitochondria-Associated Membranes (MAMs) play a role?
393 *Biochim Biophys Acta Mol Basis Dis* **1866**, 165752 (2020).
- 394 4. A. Meltzer, J. Van de Water, The Role of the Immune System in Autism Spectrum
395 Disorder. *Neuropsychopharmacology* **42**, 284-298 (2017).
- 396 5. A. Webers, M. T. Heneka, P. A. Gleeson, The role of innate immune responses and
397 neuroinflammation in amyloid accumulation and progression of Alzheimer's disease.
398 *Immunol Cell Biol* **98**, 28-41 (2020).
- 399 6. A. De Virgilio *et al.*, Parkinson's disease: Autoimmunity and neuroinflammation.
400 *Autoimmun Rev* **15**, 1005-1011 (2016).
- 401 7. Y. Lu, K. Li, Y. Hu, X. Wang, Expression of Immune Related Genes and Possible
402 Regulatory Mechanisms in Alzheimer's Disease. *Front Immunol* **12**, 768966 (2021).
- 403 8. X. Zhang *et al.*, Immune Profiling of Parkinson's Disease Revealed Its Association With
404 a Subset of Infiltrating Cells and Signature Genes. *Front Aging Neurosci* **13**, 605970
405 (2021).
- 406 9. F. Horiuchi *et al.*, Identification of aberrant innate and adaptive immunity based on
407 changes in global gene expression in the blood of adults with autism spectrum disorder. *J*
408 *Neuroinflammation* **18**, 102 (2021).
- 409 10. S. G. Fillman, D. Sinclair, S. J. Fung, M. J. Webster, C. Shannon Weickert, Markers of
410 inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar
411 disorder. *Transl Psychiatry* **4**, e365 (2014).
- 412 11. P. Saetre *et al.*, Inflammation-related genes up-regulated in schizophrenia brains. *BMC*
413 *Psychiatry* **7**, 46 (2007).
- 414 12. H. Q. Cai *et al.*, Increased macrophages and changed brain endothelial cell gene
415 expression in the frontal cortex of people with schizophrenia displaying inflammation.
416 *Mol Psychiatry* **25**, 761-775 (2020).
- 417 13. Y. Zhang *et al.*, Cortical grey matter volume reduction in people with schizophrenia is
418 associated with neuro-inflammation. *Transl Psychiatry* **6**, e982 (2016).
- 419 14. D. W. Volk, Role of microglia disturbances and immune-related marker abnormalities in
420 cortical circuitry dysfunction in schizophrenia. *Neurobiol Dis* **99**, 58-65 (2017).
- 421 15. M. J. Gandal *et al.*, Shared molecular neuropathology across major psychiatric disorders
422 parallels polygenic overlap. *Science* **359**, 693-697 (2018).
- 423 16. M. J. Gandal *et al.*, Transcriptome-wide isoform-level dysregulation in ASD,
424 schizophrenia, and bipolar disorder. *Science* **362**, (2018).
- 425 17. N. Yuan, Y. Chen, Y. Xia, J. Dai, C. Liu, Inflammation-related biomarkers in major
426 psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43
427 meta-analyses. *Transl Psychiatry* **9**, 233 (2019).
- 428 18. B. A. t Hart, W. F. den Dunnen, Commentary on special issue: CNS diseases and the
429 immune system. *J Neuroimmune Pharmacol* **8**, 757-759 (2013).
- 430 19. H. E. Gendelman, Neural immunity: Friend or foe? *J Neurovirol* **8**, 474-479 (2002).

- 431 20. S. Mitra *et al.*, Gender-specific brain regional variation of neurons, endogenous estrogen,
432 neuroinflammation and glial cells during rotenone-induced mouse model of Parkinson's
433 disease. *Neuroscience* **292**, 46-70 (2015).
- 434 21. R. V. Silva *et al.*, Contribution of Tissue Inflammation and Blood-Brain Barrier
435 Disruption to Brain Softening in a Mouse Model of Multiple Sclerosis. *Front Neurosci*
436 **15**, 701308 (2021).
- 437 22. T. Owens, H. Wekerle, J. Antel, Genetic models for CNS inflammation. *Nat Med* **7**, 161-
438 166 (2001).
- 439 23. R. Dantzer, Neuroimmune Interactions: From the Brain to the Immune System and Vice
440 Versa. *Physiol Rev* **98**, 477-504 (2018).
- 441 24. I. W. Nasr, Y. Chun, S. Kannan, Neuroimmune responses in the developing brain
442 following traumatic brain injury. *Exp Neurol* **320**, 112957 (2019).
- 443 25. C. D'Mello, M. G. Swain, Immune-to-Brain Communication Pathways in Inflammation-
444 Associated Sickness and Depression. *Curr Top Behav Neurosci* **31**, 73-94 (2017).
- 445 26. K. W. Kelley *et al.*, Cytokine-induced sickness behavior. *Brain Behav Immun* **17 Suppl**
446 **1**, S112-118 (2003).
- 447 27. M. Lyman, D. G. Lloyd, X. Ji, M. P. Vizcaychipi, D. Ma, Neuroinflammation: the role
448 and consequences. *Neurosci Res* **79**, 1-12 (2014).
- 449 28. K. Ozawa *et al.*, Immune activation during pregnancy in mice leads to dopaminergic
450 hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal
451 model of schizophrenia. *Biol Psychiatry* **59**, 546-554 (2006).
- 452 29. S. Vuillermot, L. Weber, J. Feldon, U. Meyer, A longitudinal examination of the
453 neurodevelopmental impact of prenatal immune activation in mice reveals primary
454 defects in dopaminergic development relevant to schizophrenia. *J Neurosci* **30**, 1270-
455 1287 (2010).
- 456 30. C. R. Lammert, J. R. Lukens, Modeling Autism-Related Disorders in Mice with Maternal
457 Immune Activation (MIA). *Methods Mol Biol* **1960**, 227-236 (2019).
- 458 31. D. W. Volk, D. A. Lewis, Early developmental disturbances of cortical inhibitory
459 neurons: contribution to cognitive deficits in schizophrenia. *Schizophr Bull* **40**, 952-957
460 (2014).
- 461 32. J. W. Lee *et al.*, Neuro-inflammation induced by lipopolysaccharide causes cognitive
462 impairment through enhancement of beta-amyloid generation. *J Neuroinflammation* **5**, 37
463 (2008).
- 464 33. T. D. Purves-Tyson *et al.*, Increased Macrophages and C1qA, C3, C4 Transcripts in the
465 Midbrain of People With Schizophrenia. *Front Immunol* **11**, 2002 (2020).
- 466 34. S. Mukherjee, Immune gene network of neurological diseases: Multiple sclerosis (MS),
467 Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD).
468 *Heliyon* **7**, e08518 (2021).
- 469 35. W. S. Liang *et al.*, Gene expression profiles in anatomically and functionally distinct
470 regions of the normal aged human brain. *Physiol Genomics* **28**, 311-322 (2007).
- 471 36. E. M. Blalock, H. M. Buechel, J. Popovic, J. W. Geddes, P. W. Landfield, Microarray
472 analyses of laser-captured hippocampus reveal distinct gray and white matter signatures
473 associated with incipient Alzheimer's disease. *J Chem Neuroanat* **42**, 118-126 (2011).
- 474 37. B. Zhang *et al.*, Integrated systems approach identifies genetic nodes and networks in
475 late-onset Alzheimer's disease. *Cell* **153**, 707-720 (2013).
- 476 38. E. C. Psych *et al.*, The PsychENCODE project. *Nat Neurosci* **18**, 1707-1712 (2015).
- 477 39. I. Voineagu *et al.*, Transcriptomic analysis of autistic brain reveals convergent molecular
478 pathology. *Nature* **474**, 380-384 (2011).

- 479 40. M. L. Chow *et al.*, Genome-wide expression assay comparison across frozen and fixed
480 postmortem brain tissue samples. *BMC Genomics* **12**, 449 (2011).
- 481 41. K. Garbett *et al.*, Immune transcriptome alterations in the temporal cortex of subjects
482 with autism. *Neurobiol Dis* **30**, 303-311 (2008).
- 483 42. G. E. Hoffman *et al.*, CommonMind Consortium provides transcriptomic and epigenomic
484 data for Schizophrenia and Bipolar Disorder. *Sci Data* **6**, 180 (2019).
- 485 43. C. Chen *et al.*, The transcription factor POU3F2 regulates a gene coexpression network in
486 brain tissue from patients with psychiatric disorders. *Sci Transl Med* **10**, (2018).
- 487 44. T. A. Lanz *et al.*, Postmortem transcriptional profiling reveals widespread increase in
488 inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and
489 hippocampus among matched tetrads of controls with subjects diagnosed with
490 schizophrenia, bipolar or major depressive disorder. *Transl Psychiatry* **9**, 151 (2019).
- 491 45. K. Iwamoto, M. Bundo, T. Kato, Altered expression of mitochondria-related genes in
492 postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by
493 large-scale DNA microarray analysis. *Hum Mol Genet* **14**, 241-253 (2005).
- 494 46. L. C. Chang *et al.*, A conserved BDNF, glutamate- and GABA-enriched gene module
495 related to human depression identified by coexpression meta-analysis and DNA variant
496 genome-wide association studies. *PLoS One* **9**, e90980 (2014).
- 497 47. A. Dumitriu *et al.*, Integrative analyses of proteomics and RNA transcriptomics implicate
498 mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease.
499 *BMC Med Genomics* **9**, 5 (2016).
- 500 48. Y. Zhang, M. James, F. A. Middleton, R. L. Davis, Transcriptional analysis of multiple
501 brain regions in Parkinson's disease supports the involvement of specific protein
502 processing, energy metabolism, and signaling pathways, and suggests novel disease
503 mechanisms. *Am J Med Genet B Neuropsychiatr Genet* **137B**, 5-16 (2005).
- 504 49. B. Zheng *et al.*, PGC-1alpha, a potential therapeutic target for early intervention in
505 Parkinson's disease. *Sci Transl Med* **2**, 52ra73 (2010).
- 506 50. B. E. Riley *et al.*, Systems-based analyses of brain regions functionally impacted in
507 Parkinson's disease reveals underlying causal mechanisms. *PLoS One* **9**, e102909 (2014).
- 508 51. P. R. Maycox *et al.*, Analysis of gene expression in two large schizophrenia cohorts
509 identifies multiple changes associated with nerve terminal function. *Mol Psychiatry* **14**,
510 1083-1094 (2009).
- 511 52. S. Narayan *et al.*, Molecular profiles of schizophrenia in the CNS at different stages of
512 illness. *Brain Res* **1239**, 235-248 (2008).
- 513 53. A. P. Davis *et al.*, The Comparative Toxicogenomics Database: update 2019. *Nucleic
514 Acids Res* **47**, D948-D954 (2019).
- 515 54. S. Bhattacharya *et al.*, ImmPort, toward repurposing of open access immunological assay
516 data for translational and clinical research. *Sci Data* **5**, 180015 (2018).
- 517 55. M. C. Diaz-Ramos, P. Engel, R. Bastos, Towards a comprehensive human cell-surface
518 immunome database. *Immunol Lett* **134**, 183-187 (2011).
- 519 56. K. Breuer *et al.*, InnateDB: systems biology of innate immunity and beyond--recent
520 updates and continuing curation. *Nucleic Acids Res* **41**, D1228-1233 (2013).
- 521 57. A. Liberzon *et al.*, Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**,
522 1739-1740 (2011).
- 523 58. C. The Gene Ontology, The Gene Ontology Resource: 20 years and still GOing strong.
524 *Nucleic Acids Res* **47**, D330-D338 (2019).
- 525 59. M. Kanehisa, S. Goto, KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids
526 Res* **28**, 27-30 (2000).

- 527 60. R. Birnbaum *et al.*, Investigating the neuroimmunogenic architecture of schizophrenia.
528 *Mol Psychiatry* **23**, 1251-1260 (2018).
- 529 61. M. Zhang, X. Wang, X. Chen, Q. Zhang, J. Hong, Novel Immune-Related Gene
530 Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
531 *Front Genet* **11**, 363 (2020).
- 532 62. H. Yang, K. Zhao, H. Kang, M. Wang, A. Wu, Exploring immune-related genes with
533 prognostic value in microenvironment of breast cancer from TCGA database. *Medicine*
534 (*Baltimore*) **99**, e19561 (2020).
- 535 63. S. Spitsin, K. E. Stevens, S. D. Douglas, Expression of substance P, neurokinin-1
536 receptor and immune markers in the brains of individuals with HIV-associated
537 neuropathology. *J Neurol Sci* **334**, 18-23 (2013).
- 538 64. P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network
539 analysis. *BMC Bioinformatics* **9**, 559 (2008).
- 540 65. C. Brainstorm *et al.*, Analysis of shared heritability in common disorders of the brain.
541 *Science* **360**, (2018).
- 542 66. S. Asadi, T. C. Theoharides, Corticotropin-releasing hormone and extracellular
543 mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth
544 factor release, which is inhibited by luteolin. *J Neuroinflammation* **9**, 85 (2012).
- 545 67. A. Mashaghi *et al.*, Neuropeptide substance P and the immune response. *Cell Mol Life*
546 *Sci* **73**, 4249-4264 (2016).
- 547 68. M. Lotz *et al.*, Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and
548 -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse
549 microglial cell cultures. *J Neurochem* **94**, 289-298 (2005).
- 550 69. K. Morimoto, K. Nakajima, Role of the Immune System in the Development of the
551 Central Nervous System. *Front Neurosci* **13**, 916 (2019).
- 552 70. R. Nistico *et al.*, Synaptoimmunology - roles in health and disease. *Mol Brain* **10**, 26
553 (2017).
- 554 71. F. Novellino *et al.*, Innate Immunity: A Common Denominator between
555 Neurodegenerative and Neuropsychiatric Diseases. *Int J Mol Sci* **21**, (2020).
- 556 72. B. Korin *et al.*, High-dimensional, single-cell characterization of the brain's immune
557 compartment. *Nat Neurosci* **20**, 1300-1309 (2017).
- 558 73. D. Schottle, P. Briken, O. Tuscher, D. Turner, Sexuality in autism: hypersexual and
559 paraphilic behavior in women and men with high-functioning autism spectrum disorder.
560 *Dialogues Clin Neurosci* **19**, 381-393 (2017).
- 561 74. C. T. Lee *et al.*, Incidence of Major Depressive Disorder: Variation by Age and Sex in
562 Low-Income Individuals: A Population-Based 10-Year Follow-Up Study. *Medicine*
563 (*Baltimore*) **95**, e3110 (2016).
- 564 75. J. R. Rainville, G. E. Hodes, Inflaming sex differences in mood disorders.
565 *Neuropsychopharmacology* **44**, 184-199 (2019).
- 566 76. M. Bekhbat, G. N. Neigh, Sex differences in the neuro-immune consequences of stress:
567 Focus on depression and anxiety. *Brain Behav Immun* **67**, 1-12 (2018).
- 568 77. E. J. Connors, A. N. Shaik, M. M. Migliore, A. C. Kentner, Environmental enrichment
569 mitigates the sex-specific effects of gestational inflammation on social engagement and
570 the hypothalamic pituitary adrenal axis-feedback system. *Brain Behav Immun* **42**, 178-
571 190 (2014).
- 572 78. K. M. Lenz, L. H. Nelson, Microglia and Beyond: Innate Immune Cells As Regulators of
573 Brain Development and Behavioral Function. *Front Immunol* **9**, 698 (2018).

- 574 79. S. Parab, R. E. Quick, R. L. Matsuoka, Endothelial cell-type-specific molecular
575 requirements for angiogenesis drive fenestrated vessel development in the brain. *Elife* **10**,
576 (2021).
- 577 80. P. Goines, J. Van de Water, The immune system's role in the biology of autism. *Curr*
578 *Opin Neurol* **23**, 111-117 (2010).
- 579 81. B. K. Bitanhirwe, D. Peleg-Raibstein, F. Mouttet, J. Feldon, U. Meyer, Late prenatal
580 immune activation in mice leads to behavioral and neurochemical abnormalities relevant
581 to the negative symptoms of schizophrenia. *Neuropsychopharmacology* **35**, 2462-2478
582 (2010).
- 583 82. R. Parboosing, Y. Bao, L. Shen, C. A. Schaefer, A. S. Brown, Gestational influenza and
584 bipolar disorder in adult offspring. *JAMA Psychiatry* **70**, 677-685 (2013).
- 585 83. A. M. Simanek, H. C. Meier, Association Between Prenatal Exposure to Maternal
586 Infection and Offspring Mood Disorders: A Review of the Literature. *Curr Probl Pediatr*
587 *Adolesc Health Care* **45**, 325-364 (2015).
- 588 84. A. Caccamo, V. De Pinto, A. Messina, C. Branca, S. Oddo, Genetic reduction of
589 mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and
590 pathological deficits by restoring hippocampal gene expression signature. *J Neurosci* **34**,
591 7988-7998 (2014).
- 592 85. P. H. Reddy *et al.*, Differential loss of synaptic proteins in Alzheimer's disease:
593 implications for synaptic dysfunction. *J Alzheimers Dis* **7**, 103-117; discussion 173-180
594 (2005).
- 595 86. A. J. Russo, Increased Epidermal Growth Factor Receptor (EGFR) Associated with
596 Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism
597 Spectrum Disorders (ASDs). *J Cent Nerv Syst Dis* **6**, 79-83 (2014).
- 598 87. A. M. Durieux *et al.*, Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate
599 and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice. *Front*
600 *Behav Neurosci* **9**, 343 (2015).
- 601 88. F. Li *et al.*, Dysregulated expression of secretogranin III is involved in neurotoxin-
602 induced dopaminergic neuron apoptosis. *J Neurosci Res* **90**, 2237-2246 (2012).
- 603 89. N. Harris, R. D. Fetter, D. J. Brasier, A. Tong, G. W. Davis, Molecular Interface of
604 Neuronal Innate Immunity, Synaptic Vesicle Stabilization, and Presynaptic Homeostatic
605 Plasticity. *Neuron* **100**, 1163-1179 e1164 (2018).
- 606 90. T. Sasada, K. Azuma, J. Ohtake, Y. Fujimoto, Immune Responses to Epidermal Growth
607 Factor Receptor (EGFR) and Their Application for Cancer Treatment. *Front Pharmacol*
608 **7**, 405 (2016).
- 609 91. Network, C. Pathway Analysis Subgroup of Psychiatric Genomics, Psychiatric genome-
610 wide association study analyses implicate neuronal, immune and histone pathways. *Nat*
611 *Neurosci* **18**, 199-209 (2015).
- 612 92. D. S. Tylee *et al.*, Genetic correlations among psychiatric and immune-related
613 phenotypes based on genome-wide association data. *Am J Med Genet B Neuropsychiatr*
614 *Genet* **177**, 641-657 (2018).
- 615 93. K. Pape, R. Tamouza, M. Leboyer, F. Zipp, Immunoneuropsychiatry - novel perspectives
616 on brain disorders. *Nat Rev Neurol* **15**, 317-328 (2019).
- 617 94. F. A. Costa-Pinto, J. Palermo-Neto, Neuroimmune interactions in stress.
618 *Neuroimmunomodulation* **17**, 196-199 (2010).
- 619 95. P. C. Haddick *et al.*, A Common Variant of IL-6R is Associated with Elevated IL-6
620 Pathway Activity in Alzheimer's Disease Brains. *J Alzheimers Dis* **56**, 1037-1054 (2017).

- 621 96. I. E. Jansen *et al.*, Genome-wide meta-analysis identifies new loci and functional
622 pathways influencing Alzheimer's disease risk. *Nat Genet* **51**, 404-413 (2019).
- 623 97. S. Tsagarakis, A. Grossman, Corticotropin-releasing hormone: interactions with the
624 immune system. *Neuroimmunomodulation* **1**, 329-334 (1994).
- 625 98. M. O'Kane, E. P. Murphy, B. Kirby, The role of corticotropin-releasing hormone in
626 immune-mediated cutaneous inflammatory disease. *Exp Dermatol* **15**, 143-153 (2006).
- 627 99. P. Y. Pan, K. Tammimies, S. Bolte, The Association Between Somatic Health, Autism
628 Spectrum Disorder, and Autistic Traits. *Behav Genet* **50**, 233-246 (2020).
- 629 100. J. Xiong *et al.*, Neurological Diseases With Autism Spectrum Disorder: Role of ASD
630 Risk Genes. *Front Neurosci* **13**, 349 (2019).
- 631 101. S. A. Khan *et al.*, Alzheimer's Disease and Autistic Spectrum Disorder: Is there any
632 Association? *CNS Neurol Disord Drug Targets* **15**, 390-402 (2016).
- 633 102. S. Starkstein, S. Gellar, M. Parlier, L. Payne, J. Piven, High rates of parkinsonism in
634 adults with autism. *J Neurodev Disord* **7**, 29 (2015).
- 635 103. J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe, J. D. Storey, The sva package for
636 removing batch effects and other unwanted variation in high-throughput experiments.
637 *Bioinformatics* **28**, 882-883 (2012).
- 638 104. S. Durinck, P. T. Spellman, E. Birney, W. Huber, Mapping identifiers for the integration
639 of genomic datasets with the R/Bioconductor package biomaRt. *Nat Protoc* **4**, 1184-1191
640 (2009).
- 641 105. G. Yu, L. G. Wang, Y. Han, Q. Y. He, clusterProfiler: an R package for comparing
642 biological themes among gene clusters. *OMICS* **16**, 284-287 (2012).
- 643 106. A. C. Zambon *et al.*, GO-Elite: a flexible solution for pathway and ontology over-
644 representation. *Bioinformatics* **28**, 2209-2210 (2012).
- 645 107. U. Raudvere *et al.*, g:Profiler: a web server for functional enrichment analysis and
646 conversions of gene lists (2019 update). *Nucleic Acids Res* **47**, W191-W198 (2019).
- 647 108. J. D. Dougherty, E. F. Schmidt, M. Nakajima, N. Heintz, Analytical approaches to RNA
648 profiling data for the identification of genes enriched in specific cells. *Nucleic Acids Res*
649 **38**, 4218-4230 (2010).
- 650 109. Y. Zhang *et al.*, Purification and Characterization of Progenitor and Mature Human
651 Astrocytes Reveals Transcriptional and Functional Differences with Mouse. *Neuron* **89**,
652 37-53 (2016).
- 653 110. C. A. de Leeuw, J. M. Mooij, T. Heskes, D. Posthuma, MAGMA: generalized gene-set
654 analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219 (2015).

655

656

657

658 **Acknowledgments:**

659 Published microarray datasets analyzed in this study are available on Gene Expression Omnibus
660 (accession No. GSE28521, GSE28475, GSE35978, GSE53987, GSE17612, GSE12649,
661 GSE21138, GSE54567, GSE54568, GSE54571, GSE54572, GSE29555, GSE5281, GSE28146,
662 GSE20168, GSE20295, GSE54282, GSE68719 and GSE11223), ArrayExpress (accession no. E-
663 MTAB-184), or directly from the study authors.

664 RNA-seq data (available on Synapse with accession numbers syn4590909 and syn4587609, with
665 access governed by NIMH Repository and Genomics Resource) were generated as part of the
666 PsychENCODE Consortium, supported by grants U01MH103339, U01MH103365,
667 U01MH103392, U01MH103340, U01MH103346, R01MH105472, R01MH094714,
668 R01MH105898, R21MH102791, R21MH105881, R21MH103877, and P50MH106934 awarded
669 to Schahram Akbarian (Icahn School of Medicine at Mount Sinai), Gregory Crawford (Duke),
670 Stella Dracheva (Icahn School of Medicine at Mount Sinai), Peggy Farnham (USC), Mark
671 Gerstein (Yale), Daniel Geschwind (UCLA), Thomas M. Hyde (LIBD), Andrew Jaffe (LIBD),
672 James A. Knowles (USC), Chunyu Liu (SUNY), Dalila Pinto (Icahn School of Medicine at
673 Mount Sinai), Nenad Sestan (Yale), Pamela Sklar (Icahn School of Medicine at Mount Sinai),
674 Matthew State (UCSF), Patrick Sullivan (UNC), Flora Vaccarino (Yale), Sherman Weissman
675 (Yale), Kevin White (UChicago), and Peter Zandi (JHU).

676 RNA-seq data from the CommonMind Consortium used in this study (Synapse accession no.
677 syn2759792) was supported by funding from Takeda Pharmaceuticals Company, F. Hoffman-La
678 Roche and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405,

679 R01MH097276, RO1-MH-075916, P50M096891, P50MH084053S1, R37MH057881,
680 R37MH057881S1, HHSN271201300031C, AG02219, AG05138, and MH06692.

681 RNA-seq data from the ROSMAP were provided by the Rush Alzheimer's Disease Center, Rush
682 University Medical Center, Chicago. Data collection was supported through funding by NIA
683 grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917
684 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac),
685 R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus
686 RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP
687 AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome
688 sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health
689 (ROSMAP), and the Translational Genomics Research Institute (genomic). Brain tissue for the
690 study was obtained from the following brain bank collections: the Mount Sinai NIH Brain and
691 Tissue Repository, the University of Pennsylvania Alzheimer's Disease Core Center, the
692 University of Pittsburgh NeuroBioBank and Brain and Tissue Repositories, the Harvard Brain
693 Bank as part of the Autism Tissue Project (ATP), the Stanley Medical Research Institute, and the
694 NIMH Human Brain Collection Core.

695 We thank Richard F. Kopp, Mingrui Yu, and Yan Xia for reviewing the manuscript.

696 **Funding:**

697 National Natural Science Foundation of China Nos. 82022024

698 National Natural Science Foundation of China Nos. 31970572

699 National Natural Science Foundation of China Nos. 31871276

700 the National Key R&D Project of China Grants No. 2016YFC1306000

701 the National Key R&D Project of China Grants No. 2017YFC0908701

702 Innovation-driven Project of Central South University Grant Nos. 2020CX003

703 NIH grants U01 MH122591

704 NIH grants 1U01MH116489.

705 NIH grants 1R01MH110920.

706 **Author contributions:**

707 Conceptualization: YC, CL

708 Methodology: YC, JD, LT

709 Investigation: YC, JD, QL, QH, ML, JZ

710 Visualization: YC

711 Funding acquisition: CL, CC

712 Project administration: CL

713 Supervision: CL, CC

714 Writing – original draft: YC, JD, CL,

715 Writing – review & editing: YC, CL, JD, CC, CW

716 **Competing interests:** Authors declare that they have no competing interests

717 **Data and materials availability:** All data are available in the main text or the supplementary
718 materials."

719

720 **Supplementary Materials**

721 Materials and Methods

722 Supplementary Text

723 Figs. S1 to S8

724 Tables. S1 to S10

725 References (47-56, 95-103)

726

727

728 **Fig. 1. Differential expression of immune genes in six disorders.** A. Volcano plot for each
729 disorder. B. Effect size correlation between microarray data and RNA-seq data.

730 **Fig. 2. Comparison of the effect size of differentially expressed IRGs among**
731 **neuropsychiatric disease pairs.** A. Numbers of up-regulated and downregulated dIRGs in the
732 six disorders. Red represents up-regulated dIRGs, blue represents down-regulated dIRGs. B.
733 Cluster tree of scaled effect size for all disorders based on 1275 IRGs for their fold changes. C.
734 Significant sex differences by effect size in ASD and MDD. D. dIRGs shared across disorders:
735 CRH and TAC1. *: $\text{fdr } q.\text{value} < 0.05$; ** $\text{fdr } q.\text{value} < 0.01$; *** $\text{fdr } q.\text{value} < 0.001$


736 **Fig. 3. Comparing dIRG-associated function across disorders.** A. UpSet plot of dIRGs
737 overlap between pairs of disorders. Dark cells and lines indicate that the set participates in the
738 intersection. B. The doughnut chart shows the percentages of different IRGs types. C. UpSet plot
739 of differential immune pathways overlap. The black dots and the black line show the overlapping
740 dIRG-pathways between pairs of disorders. Cells that are dark indicate that it participates in the
741 intersection. D. The doughnut chart shows the percentages of overlapping dIRG-pathways. E.
742 Gene ontology enrichment analysis results of six pathways shared by dIRGs of all six disorders.

743 **Fig. 4. Shared immune-related coexpression modules** A. Robust gene dendrogram obtained by
744 WGCNA. B. The multidimensional scaling plot demonstrates the relationship between modules.
745 Modules highlighted by stars are enriched in immune genes (enrichment $q\text{-value} < 0.05$). Edges
746 are weighted by the strength of correlation between eigengenes of modules. C. The top 20 hub
747 genes are plotted for the three IRM4, IRM12, and IRM14. A complete list of genes' module
748 membership (kME) is provided in data Table S8. Edges are weighted by the strength of the


749 correlation between genes. **D.** Relationships of module eigengenes and diseases. Numbers in the
750 table report the correlations of the corresponding module eigengenes and traits, with the p.values
751 printed below the correlation coefficients r values. **E.** Cell marker enrichment of shared IRMs. **F.**
752 Enrichment of the shared IRMs in pathways. Yellow: IRM4, Tan: IRM12, Cyan: IRM14





753 **Fig. 5. Disease-specific coexpression modules.** **A.** Workflow for identifying disease-specific
754 IRMs. **B.** Module preservation plot of disease-specific IRMs. The median rank and Zsummary
755 statistics of module preservation of disorder modules in background modules (y-axis) vs. module
756 size (x-axis). **C.** Pathway enrichment of disease-specific immune modules.

757




B RNAseq Replication






A


medRxiv preprint doi: <https://doi.org/10.1101/2022.02.14.22269692>; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




B




C









D




E






A



B



C

